Celsion Corp (CLSN)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Celsion Corp (CLSN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Celsion Corp ever had a stock split?
Celsion Corp Profile
| Biotechnology Industry | Healthcare Sector | Michael Tardugno CEO | NASDAQ (CM) Exchange | 15117N602 CUSIP |
| US Country | 29 Employees | - Last Dividend | 1 Mar 2022 Last Split | - IPO Date |
Overview
Celsion Corporation is a trailblazing clinical stage biotechnology company with a sharp focus on developing innovative DNA-based immunotherapies, vaccines, and targeted chemotherapies. Since its inception in 1982, the company has been dedicated to advancing the treatment of cancer through cutting-edge research and development. Headquartered in Lawrenceville, New Jersey, Celsion strives to revolutionize cancer treatment by harnessing the power of genetic science to craft therapies that precisely target and combat the disease, aiming to improve the lives of patients worldwide.
Products and Services
- GEN-1
A forefront product in Celsion Corporation's pipeline, GEN-1 represents a pioneering approach to the treatment of ovarian cancer. This DNA-based immunotherapy is designed for localized treatment, with the promise of offering a more precise, targeted intervention. By focusing on immunotherapy, GEN-1 aims to leverage the patient's own immune system to fight off cancer cells, marking a significant step forward in the treatment of ovarian cancer.
- ThermoDox
Another innovative product under development at Celsion Corporation is ThermoDox, a proprietary technology that encapsulates doxorubicin, a widely used chemotherapy drug, within heat-activated liposomes. This unique delivery system is designed to release the drug directly at the tumor site when triggered by heat, potentially minimizing the side effects associated with systemic chemotherapy distribution and maximizing the therapeutic impact on the targeted cancer cells. ThermoDox is currently being developed for various cancer indications, showcasing the versatility and potential of this approach.
- Feasibility Stage Platform Technologies
In addition to specific products like GEN-1 and ThermoDox, Celsion Corporation is also exploring two feasibility stage platform technologies. These platforms are geared towards the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. While still in the early stages, these technologies represent the cutting edge of cancer research and may pave the way for next-generation cancer treatments that are more effective, less invasive, and offer better quality of life for patients.
